Cobra Venom: From Envenomation Syndromes to Therapeutic Innovations

Snakebite envenomation, classified as a neglected tropical disease, represents a significant global health threat, particularly in Asia and Africa, where it causes between 57,000 and 100,000 deaths annually. Envenomation by cobras, especially those of the genus Naja, contributes substantially to this burden. This review explores the complexities of cobra venom composition, its associated complications, and current treatment strategies, with a focus on venom-derived therapeutic prospects.

Cobra venom is a complex mixture primarily composed of proteins and peptides that exert various toxic effects, including neurotoxicity, tissue damage, and systemic complications. Antivenom therapy remains the primary treatment for envenomation, successfully mitigating critical effects such as bleeding and paralysis. Recent research, however, has revealed that certain venom-derived molecules possess therapeutic potential, opening up new possibilities for drug development.

Despite the lethal nature of cobra envenomation, advances in antivenom therapy and emerging research into the medicinal properties of venom-derived molecules offer hope. This review highlights the dual nature of cobra venom—both as a source of severe pathology and as a potential reservoir for therapeutic agents—fostering the development of novel drugs.